Summary of the Conference Call Company Overview - **Company Name**: Jingbo Biological - **Industry**: Synthetic Biology and Biomanufacturing Key Financial Metrics - **Revenue**: 1.443 billion CNY, a year-on-year increase of 84.92% from 780 million CNY in 2023 [2] - **Net Profit**: 732 million CNY, a year-on-year increase of 144.27% [21] - **Earnings per Share**: 8.27 CNY [1] - **Gross Margin**: 92.02% [2] - **Cash Flow from Operating Activities**: 767 million CNY, a year-on-year increase of 159.55% [21] - **Debt Ratio**: 25.53% [2] - **Current Ratio**: 4.44 [2] - **R&D Investment**: 123 million CNY, accounting for 8.52% of revenue [22] Core Business Segments - **Medical Devices**: Revenue of 1.254 billion CNY, a year-on-year increase of 84.37% [21] - **Functional Skincare Products**: Revenue of 142 million CNY, accounting for 9.83% of total revenue [2] - **Raw Materials**: Rapid growth due to increased brand customer procurement [22] Innovation and Product Development - **New Product Launch**: Successfully launched injectable recombinant human collagen gel, a significant breakthrough in synthetic biology [12][17] - **Research Focus**: Emphasis on original innovation and the development of advanced structural functional proteins [25] - **Collagen Research**: The company has developed a unique theory and data system for A-type recombinant human collagen, enabling large-scale production [17][19] Market Position and Growth Strategy - **Market Expansion**: The company is actively expanding its market presence and has received FDA certifications for several products [23] - **International Patents**: Holds a total of 104 patents, including 10 international invention patents [23] - **Investor Relations**: Conducted 9 investor communication activities, including 3 performance briefings, reaching over 300 institutions and analysts [24] Future Outlook - **Vision**: Aims to become a leading international technology innovation enterprise in the field of biological materials [25] - **Sustainability**: Utilizes green and environmentally friendly production processes [25] - **Dividend Policy**: Plans to distribute a total of 266 million CNY in dividends if the proposed plan is implemented [24] Additional Insights - **Cultural Emphasis**: The company fosters a culture of innovation and risk-taking, essential for scientific research [11][15] - **Challenges in R&D**: The development of new products involves significant challenges and risks, with a focus on maintaining high standards in research [15][16] - **Collaboration**: Maintains long-term partnerships with renowned universities and medical institutions to enhance R&D capabilities [22]